Fulcrum Therapeutics Inc (FULC)
3.77
-0.23
(-5.75%)
USD |
NASDAQ |
Sep 27, 16:00
3.84
+0.07
(+1.86%)
After-Hours: 20:00
Fulcrum Therapeutics SG&A Expense (Annual): 41.67M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.67M |
| December 31, 2022 | 41.69M |
| December 31, 2021 | 30.52M |
| December 31, 2020 | 21.39M |
| Date | Value |
|---|---|
| December 31, 2019 | 13.14M |
| December 31, 2018 | 8.314M |
| December 31, 2017 | 4.499M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
13.14M
Minimum
2019
41.69M
Maximum
2022
29.68M
Average
30.52M
Median
2021
SG&A Expense (Annual) Benchmarks
| Bioventus Inc | 303.88M |
| Arcturus Therapeutics Holdings Inc | 52.87M |
| Entrada Therapeutics Inc | 32.29M |
| Johnson & Johnson | 20.11B |
| Insmed Inc | 344.50M |